- No public price. Demo request only.
- Not disclosed
- Type II
- —
- —
Pathology
Proscia Concentriq
by Proscia
Concentriq pathology platform for clinical labs and biopharma: image management, case review and AI apps, with FDA-cleared AP-Dx for primary diagnosis.
On this page
30/100Competitive
- Regulatory & Compliance24/28
FDA cleared (2 K-numbers on record)
- Clinical Integration0/26
No EHR integrations listed
- Evidence Strength0/28.8
No peer-reviewed coverage
- Vendor & Market8.4/18
Mid-tier funding and adoption
- Sentiment & Transparency2.5/14
Pricing on request, no public amounts
▸ Show all 11 dimensions▾ Hide dimension detail
- FDA clearance18/18
FDA cleared (2 K-numbers on record)
- HIPAA / SOC2 / BAA6/10
Partial attestation (one of HIPAA / SOC2 / BAA)
- EHR integrations (count)0/14
No EHR integrations listed
- Top-3 EHR coverage (Epic / Oracle / Athena)0/8
None of the top-3 EHRs covered
- Bidirectional write-back0/4
No bidirectional write-back documented
- Peer-reviewed papers0/21
No peer-reviewed coverage
- RCT / meta-analysis / systematic review0/8
No RCT, meta-analysis, or systematic review
- Funding & adoption signal8/12
Mid-tier funding and adoption
- Years in market0/6
Founded year not recorded
- Clinician sentiment (Reddit)0/9
No clinician sentiment data available
- Pricing transparency3/5
Pricing on request, no public amounts
Used by 16/20 top pharma. $130M total funding.
IMS platform + AI marketplace. Strongest pharma R&D footprint.
Bottom line
Proscia sells Concentriq, a digital pathology platform for image management, case review and AI app deployment, used by diagnostic laboratories and by pharmaceutical research teams. Its clinical version, Concentriq AP-Dx, holds two FDA 510(k) clearances as software for viewing and managing scanned slides. It fits a pathology lab moving to digital primary diagnosis, or a biopharma group running biomarker work. Agilent announced on 13 October 2026 an agreement to acquire Proscia, and the deal has not closed. A lab that needs a scanner outside the two cleared pairings, or a vendor with settled ownership before it signs, should hold off.
What is Concentriq and who sells it?
Proscia, Inc. is based in Philadelphia and was founded in 2014 by David West (CEO), Coleman Stavish (CTO) and Nathan Buchbinder (CSO), who say they started it "in our college dorm rooms." It has an office in Sligo, Ireland.
The platform has two lines. Clinical solutions cover case review in diagnostic labs. Life Sciences solutions cover biomarker research, trials and companion diagnostics. The vendor reports 12 million cases a year, more than 4,000 hospitals and clinics, more than 30,000 studies and 16 of the top 20 pharmaceutical companies.
What did Agilent agree to buy?
Agilent's agreement, reported by HIT Consultant, is worth up to $270M: $240M in cash at closing and up to $30M as an earnout. Closing is expected early in Agilent's fiscal 2027. The same report puts Proscia's trailing 12-month revenue above $18M. The two companies have had a distribution agreement since September 2022.
Funding totals vary by aggregator, from $118.3M at Indexed.vc to $129M at PitchBook and Tracxn, and a $37M Series C has been reported.
What is cleared by the FDA?
Two 510(k) records name Proscia as applicant. K230839, dated 8 February 2024, covers Concentriq Dx under product code PSY, announced as Concentriq AP-Dx with the Hamamatsu NanoZoomer S360MD scanner. K261380, dated 5 August 2026, is under product code QKQ, and Proscia's announcement says it adds the Leica Aperio GT 450 DX scanner, cloud deployment and a predetermined change control plan.
The indication is viewing and managing digital images of scanned FFPE surgical pathology slides as an aid to primary diagnosis. It excludes frozen sections, cytology and non-FFPE hematopathology. The vendor also lists CE-IVDR marking for AP-Dx.
How is security documented?
Proscia announced SOC 2 Type II certification on 3 December 2025. It has held ISO 27001 since 31 October 2023 and also holds ISO 13485. A deployment page claims HIPAA alignment.
What does the evidence say?
Proscia's release for the AP-Dx clearance says the system was non-inferior to glass-slide reads in a clinical study. KLAS named Concentriq Best in KLAS 2026 according to the vendor's page, which also says 100% of customers told KLAS they would buy it again.
How is it priced?
No price is public, and the vendor's site offers a demo request as the way in.
The verdict
A lab that has already picked a scanner and uses the Hamamatsu NanoZoomer S360MD or the Leica Aperio GT 450 DX can buy within the two 510(k) records. The two records name only those scanners, so a lab on another scanner should look at what its own scanner pairing is cleared for. For a buyer signing a multi-year contract, the Agilent deal is the open item, since roadmap, support structure and contract terms could change once it closes.
Editorial review last generated October 15, 2026. Synthesized from clinician sentiment, peer-reviewed coverage, and our editorial silo picks. Refined by hand where vendor facts change.
What it costs
All tiers are custom-quoted. The vendor does not publish per-provider list pricing.
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | — | — | No public price. Demo request only. |
Source: vendor pricing page. Last checked October 15, 2026.
What deploys cleanly
Carries FDA 510(k), SOC 2 Type II (vendor announcement, 2025-12-03), ISO 27001 (vendor-stated, 2023), ISO 13485 (vendor-stated) per vendor documentation. Independent attestation review is the buyer's responsibility before clinical deployment.
Other pathology
See the full pathology ranking
Tempus Digital Pathology
by Tempus AI
Digital pathology AI from Paige, now part of Tempus: Paige Prostate Detect (FDA De Novo, CE-IVDR) plus research-use suites.
No public price on the Tempus pages.|FDA De Novo (DEN200080) / FDA 510(k) (FullFocus viewer)
PathAI AISight
by PathAI
Cloud image management for digital pathology with AISight Dx, cleared for primary diagnosis, plus biopharma AI services.
No public price. Billing period, trial and refund not stated.|FDA 510(k)
Ibex Medical Analytics
by Ibex
AI pathology software for prostate, breast and gastric cancer. One US FDA 510(k) clearance, for prostate.
No public price. Sold to laboratories and health systems on enterprise contracts.|FDA 510(k)Sectra Pathology
by Sectra
Digital pathology image management (Sectra IDS7) with a marketplace for third-party AI apps. Sectra does not make the AI.
No public price. Contact form only.|FDA 510(k)